Chester County News and Community Website
EXTON, PA — Melior Pharmaceuticals announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . (OTCPK: ATRX) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).
Read More EXTON, PA — Melior Pharmaceuticals announced that it has signed a “letter of intent” with Adhera Therapeutics, Inc . (OTCPK: ATRX) for the acquisition of Melior’s Parkinson’s disease (PD) candidate, …
Read More
Parkinson’s Disease (PD) impacts up to one in 15 individuals in the United States. People with PD often experience symptoms that impact their movement, like tremors, shuffling feet while walking, …
Read More
BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced it successfully completed the …
Read More BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced dosing of the first …
Read More BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, is pleased to announce its …
Read More BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, reported that it has received …
Read More BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today that the protocol …
Read More BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, published data from its two double-blind, placebo-controlled …
Read MoreBERWYN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, was issued a patent (US 10,383,851) in August 2019 for …
Read More